Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 2696071, 8 pages
https://doi.org/10.1155/2017/2696071
Research Article

Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas

1Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

Correspondence should be addressed to Peeter Karihtala; if.uluo@alathirak.reteep

Received 19 December 2016; Accepted 9 February 2017; Published 9 March 2017

Academic Editor: Jaideep Banerjee

Copyright © 2017 Peeter Karihtala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Kuruvilla, A. Keating, and M. Crump, “How I treat relapsed and refractory Hodgkin lymphoma,” Blood, vol. 117, no. 16, pp. 4208–4217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Bur, K.-M. Haapasaari, T. Turpeenniemi-Hujanen et al., “Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas,” Histopathology, vol. 65, no. 3, pp. 319–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Okado-Matsumoto, A. Matsumoto, J. Fujii, and N. Taniguchi, “Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions,” The Journal of Biochemistry, vol. 127, no. 3, pp. 493–501, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-P. Declercq, C. Evrard, A. Clippe, D. V. Stricht, A. Bernard, and B. Knoops, “Crystal structure of human peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 Å resolution,” Journal of Molecular Biology, vol. 311, no. 4, pp. 751–759, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. V. L. Kinnula, S. Lehtonen, R. Sormunen et al., “Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma,” Journal of Pathology, vol. 196, no. 3, pp. 316–323, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. S. W. Kang, I. C. Baines, and S. G. Rhee, “Characterization of a mammalian peroxiredoxin that contains one conserved cysteine,” Journal of Biological Chemistry, vol. 273, no. 11, pp. 6303–6311, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Rani, C. A. Neumann, C. Shao, and J. A. Tischfield, “Prdx1 deficiency in mice promotes tissue specific loss of heterozygosity mediated by deficiency in DNA repair and increased oxidative stress,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 735, no. 1-2, pp. 39–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Cao, J. Schulte, A. Knight et al., “Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity,” EMBO Journal, vol. 28, no. 10, pp. 1505–1517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Y.-H. Han, H.-S. Kim, J.-M. Kim, S.-K. Kim, D.-Y. Yu, and E.-Y. Moon, “Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence,” FEBS Letters, vol. 579, no. 21, pp. 4897–4902, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Karihtala and Y. Soini, “Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies,” APMIS, vol. 115, no. 2, pp. 81–103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Itoh, J. Mimura, and M. Yamamoto, “Discovery of the negative regulator of Nrf2, keap1: a historical overview,” Antioxidants and Redox Signaling, vol. 13, no. 11, pp. 1665–1678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Hu, C. L.-L. Saw, R. Yu, and A.-N. T. Kong, “Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory,” Antioxidants and Redox Signaling, vol. 13, no. 11, pp. 1679–1698, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Cheng, C.-H. Ku, and R. C. M. Siow, “Regulation of the Nrf2 antioxidant pathway by microRNAs: new players in micromanaging redox homeostasis,” Free Radical Biology and Medicine, vol. 64, pp. 4–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. Pitcher and N. S. C. Van Oers, “T-cell receptor signal transmission: who gives an ITAM?” Trends in Immunology, vol. 24, no. 10, pp. 554–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Deans, H. Li, and M. J. Polyak, “CD20-mediated apoptosis: signalling through lipid rafts,” Immunology, vol. 107, no. 2, pp. 176–182, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Schneider and G. Hübinger, “Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family,” Leukemia and Lymphoma, vol. 43, no. 7, pp. 1355–1366, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. S. H. Swerdlow, E. Campo, N. L. Harris et al., “Mature B-cell neoplasms,” in WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, pp. 179–268, IARC Press, Lyon, France, 4th edition, 2008. View at Google Scholar
  18. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method,” Methods, vol. 25, pp. 402–408, 2001. View at Google Scholar
  19. R. T. Dorr, “Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics,” Seminars in Oncology, vol. 19, no. 2, pp. 3–8, 1992. View at Google Scholar · View at Scopus
  20. J. Fang, H. Nakamura, and A. K. Iyer, “Tumor-targeted induction of oxystress for cancer therapy,” Journal of Drug Targeting, vol. 15, no. 7-8, pp. 475–486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Pourahmad, M. Amirmostofian, F. Kobarfard, and J. Shahraki, “Biological reactive intermediates that mediate dacarbazine cytotoxicity,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 1, pp. 89–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Tome, J. B. Frye, D. L. Coyle et al., “Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance,” Experimental and Therapeutic Medicine, vol. 3, no. 5, pp. 845–852, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. L. Kuusisto, K.-M. Haapasaari, T. Turpeenniemi-Hujanen et al., “High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index,” Journal of Clinical Pathology, vol. 68, no. 7, pp. 552–556, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Meng, J. Wu, C. Pan et al., “Genetic and epigenetic down-regulation of MicroRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD,” Gastroenterology, vol. 145, no. 2, pp. 426–436, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Sánchez-Espiridión, A. M. Martín-Moreno, C. Montalbán et al., “MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma,” British Journal of Haematology, vol. 162, no. 3, pp. 336–347, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Jones, J. P. Nourse, C. Keane, A. Bhatnagar, and M. K. Gandhi, “Plasma microRNA are disease response biomarkers in classical hodgkin lymphoma,” Clinical Cancer Research, vol. 20, no. 1, pp. 253–264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Yang, Y. Yao, G. Eades, Y. Zhang, and Q. Zhou, “MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism,” Breast Cancer Research and Treatment, vol. 129, no. 3, pp. 983–991, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. N. M. Shah, S. A. Rushworth, M. Y. Murray, K. M. Bowles, and D. J. MacEwan, “Understanding the role of NRF2-regulated miRNAs in human malignancies,” Oncotarget, vol. 4, no. 8, pp. 1130–1142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. L. M. Solis, C. Behrens, W. Dong et al., “Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features,” Clinical Cancer Research, vol. 16, no. 14, pp. 3743–3753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Soini, M. Eskelinen, P. Juvonen et al., “Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma,” Pathology Research and Practice, vol. 210, no. 1, pp. 35–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Hartikainen, M. Tengström, V.-M. Kosma, V. L. Kinnula, A. Mannermaa, and Y. Soini, “Genetic polymorphisms and protein expression of NRF2 and sulfiredoxin predict survival outcomes in breast cancer,” Cancer Research, vol. 72, no. 21, pp. 5537–5546, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Singh, S. Boldin-Adamsky, R. K. Thimmulappa et al., “RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy,” Cancer Research, vol. 68, no. 19, pp. 7975–7984, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C.-F. Huang, L. Zhang, S.-R. Ma et al., “Clinical significance of keap1 and Nrf2 in oral squamous cell carcinoma,” PLOS ONE, vol. 8, no. 12, Article ID e83479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Wang, A. J. G. Diaz, and Y. Yen, “The role of peroxiredoxin II in chemoresistance of breast cancer cells,” Breast Cancer: Targets and Therapy, vol. 6, pp. 73–80, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. P. S. Smith-Pearson, M. Kooshki, D. R. Spitz, L. B. Poole, W. Zhao, and M. E. Robbins, “Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H2O2,” Free Radical Biology and Medicine, vol. 45, no. 8, pp. 1178–1189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Kubota, K. Mukaihara, A. Yoshida, H. Tsuda, A. Kawai, and T. Kondo, “Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma,” Journal of Proteomics, vol. 91, pp. 393–404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. C. McDonald, J. Muhlbauer, G. Perlmutter, K. Taparra, and S. A. Phelan, “Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity,” International Journal of Oncology, vol. 45, no. 1, pp. 219–226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Suenaga, Y. Kuramitsu, Y. Wang et al., “Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells,” Anticancer Research, vol. 33, no. 11, pp. 4821–4826, 2013. View at Google Scholar · View at Scopus
  39. Q.-K. Sun, J.-Y. Zhu, W. Wang et al., “Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma,” Medical Oncology, vol. 31, no. 1, article no. 786, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. E. V. Kalinina, T. T. Berezov, A. A. Shtil' et al., “Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation,” Bulletin of Experimental Biology and Medicine, vol. 153, no. 6, pp. 879–882, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. Q. J. Guo, J. N. Mills, S. G. Bandurraga et al., “MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer,” Breast Cancer Research, vol. 15, no. 4, article no. R70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Gaj and R. Zagozdzon, “In silico analysis of microRNA-510 as a potential oncomir in human breast cancer,” Breast Cancer Research, vol. 16, no. 2, article 403, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. X. Zhang, G. Guo, G. Wang et al., “Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma,” Molecular Medicine Reports, vol. 12, no. 6, pp. 8021–8031, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Diao, J.-F. Zhang, H. Wang et al., “Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma,” Proteomics, vol. 10, no. 20, pp. 3723–3731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. H. J. Cho, J. K. Kim, J. S. Nam et al., “High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation,” Clinical Biochemistry, vol. 48, no. 16-17, pp. 1073–1078, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Xu, X. Bu, C. Dai, and C. Shang, “High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients,” Tumor Biology, vol. 36, no. 6, pp. 4773–4776, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Köberle, B. Kronenberger, T. Pleli et al., “Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma,” European Journal of Cancer, vol. 49, no. 16, pp. 3442–3449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. K. K. Li, J. C. Pang, K. M. Lau et al., “MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3),” Brain Pathology, vol. 23, no. 4, pp. 413–425, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. H.-C. He, J.-G. Zhu, X.-B. Chen et al., “MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer,” FEBS Letters, vol. 586, no. 16, pp. 2451–2458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Tian, Y.-X. Fang, J.-L. Xue, and J.-Z. Chen, “Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro,” PlOS one, vol. 8, no. 9, Article ID e75885, 2013. View at Google Scholar · View at Scopus
  51. L. Chen, L. Han, K. Zhang et al., “VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling,” Neuro-Oncology, vol. 14, no. 8, pp. 1026–1036, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Ma, W. Dai, A. Sang, X. Yang, and C. Gao, “Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 12, pp. 8833–8840, 2014. View at Google Scholar · View at Scopus
  53. S. Han, C. Cao, T. Tang et al., “ROBO3 promotes growth and metastasis of pancreatic carcinoma,” Cancer Letters, vol. 366, no. 1, pp. 61–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. X. Wang, Y. Ren, Z. Wang et al., “Down-regulation of 5S rRNA by miR-150 and miR-383 enhances c-Myc-rpL11 interaction and inhibits proliferation of esophageal squamous carcinoma cells,” FEBS Letters, vol. 589, no. 24, pp. 3989–3997, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Chen, H. Guan, C. Gu, Y. Cao, J. Shao, and F. Wang, “miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL,” Tumor Biology, vol. 37, no. 2, pp. 2497–2507, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. O. Merkel, F. Hamacher, R. Griessl et al., “Oncogenic role of MIR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation,” The Journal of Pathology, vol. 236, no. 4, pp. 445–456, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. J. H. Gibcus, L. P. Tan, G. Harms et al., “Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile,” Neoplasia, vol. 11, no. 2, pp. 167–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. I. Slezak-Prochazka, J. Kluiver, D. D. Jong et al., “Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma,” Oncotarget, vol. 7, no. 3, pp. 2391–2400, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. U. D'Oro, I. Munitic, G. Chacko, T. Karpova, J. McNally, and J. D. Ashwell, “Regulation of constitutive TCR internalization by the ζ-chain,” Journal of Immunology, vol. 169, no. 11, pp. 6269–6278, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Leidinger, C. Backes, B. Meder, E. Meese, and A. Keller, “The human miRNA repertoire of different blood compounds,” BMC Genomics, vol. 15, article 474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. F. A. Alashti and Z. Minuchehr, “MiRNAs which target CD3 subunits could be potential biomarkers for cancers,” PLOS ONE, vol. 8, no. 11, Article ID e78790, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Sangokoya, M. J. Telen, and J.-T. Chi, “microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease,” Blood, vol. 116, no. 20, pp. 4338–4348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. A. U. Khan, M. G. Rathore, N. Allende-Vega et al., “Human leukemic cells performing oxidative phosphorylation (OXPHOS) generate an antioxidant response independently of reactive oxygen species (ROS) production,” EBioMedicine, vol. 3, pp. 43–53, 2016. View at Publisher · View at Google Scholar · View at Scopus